LLY surges with FDA approval and strong 2025 growth
Watch: Monitor Foundayo's market penetration and quarterly sales as indicators of LLY's expanding weight-loss franchise performance.
Full analysis
Eli Lilly's 2025 revenue jumped 45% to $65.2 billion, powered by Zepbound's $13.5 billion (up 175%) and Mounjaro's nearly $23 billion sales. The newly FDA-approved GLP-1 pill, Foundayo, could expand its market beyond injectables, marking a key growth driver. LLY also outperformed the S&P 500 during the 2022 crash, reinforcing its defensive quality. Morgan Stanley maintains an overweight rating on the stock.
This robust revenue growth, product approval, and defensive market performance position LLY for continued earnings momentum amid competitive pressures and valuation headwinds.
Evidence
7 older signals
Get alerted when LLY changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.